🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

19+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 19 of 19 recruiting trials for “Extranodal nasal NK/T cell lymphoma

Phase 2RecruitingNCT07380984

PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL

🏥 Ruijin Hospital📍 1 site📅 Started Mar 2026View details ↗
Phase 1, PHASE2RecruitingNCT06966154

A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL

🏥 Fudan University📍 1 site📅 Started May 2025View details ↗
Phase 2RecruitingNCT07000617

A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma

🏥 Peking University Cancer Hospital & Institute📍 3 sites📅 Started Mar 2025View details ↗
Phase 1RecruitingNCT06732492

RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies

🏥 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology📍 1 site📅 Started Oct 2024View details ↗
Enrolling by InvitationNCT07450040

Efficacy and Safety of Tislelizumab Combined With Gemcitabine and Peraspartase in the Treatment of Patients With Primary Stage I-II NK/T Cell Lymphoma

🏥 Eye & ENT Hospital of Fudan University📍 1 site📅 Started Sep 2024View details ↗
Phase 1, PHASE2RecruitingNCT06559553

"Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCL

🏥 Mingzhi Zhang📍 1 site📅 Started Sep 2024View details ↗
Phase 2RecruitingNCT06824883

Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma

🏥 Peking Union Medical College Hospital📍 1 site📅 Started May 2024View details ↗
Phase 1, PHASE2RecruitingNCT06376721

Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma

👨‍⚕️ Liang Wang, M.D., Beijing Tongren Hospital📍 1 site📅 Started Apr 2024View details ↗
Phase 2RecruitingNCT06314334

Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma

👨‍⚕️ Rong Tao, MD, Fudan Cancer Hospital📍 6 sites📅 Started Mar 2024View details ↗
RecruitingNCT06362148

Circulating Tumor DNA in Peripheral T-cell Lymphomas

👨‍⚕️ Francesco A d'Amore, MD, DMSc, Aarhus University Hospital and Aarhus University📍 1 site📅 Started Mar 2024View details ↗
NARecruitingNCT06069830

PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma

🏥 Ruijin Hospital📍 1 site📅 Started Dec 2023View details ↗
NARecruitingNCT05662540

PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma

🏥 Ruijin Hospital📍 1 site📅 Started May 2023View details ↗
Phase 2RecruitingNCT05833893

Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma

👨‍⚕️ Yu Zhao, Graduate, Chief📍 1 site📅 Started May 2023View details ↗
Phase 2RecruitingNCT05477264

Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal Type

🏥 Won Seog Kim📍 1 site📅 Started Mar 2023View details ↗
Phase 2RecruitingNCT04417166

Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma

👨‍⚕️ Stefano Luminari, MD, Ematologia, AUSL IRCCS Reggio Emilia📍 2 sites📅 Started Feb 2022View details ↗
Phase 3RecruitingNCT04365036

A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)

🏥 Sun Yat-sen University📍 1 site📅 Started May 2020View details ↗
Phase 2RecruitingNCT02859402

Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas

🏥 Keimyung University Dongsan Medical Center📍 2 sites📅 Started Dec 2016View details ↗
Phase 2RecruitingNCT02974647

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

👨‍⚕️ Alison Moskowitz, MD, Memorial Sloan Kettering Cancer Center📍 10 sites📅 Started Nov 2016View details ↗
Phase 1RecruitingNCT01555892

Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE

👨‍⚕️ Helen E Heslop, MD, Baylor College of Medicine📍 3 sites📅 Started Jan 2013View details ↗

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →